Concepedia

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

Samer Gawrieh, Mazen Noureddin, Nicole Loo, Rizwana Mohseni, Vivek Awasty, Kenneth Cusi, Kris V. Kowdley, Michelle Lai, Eugene R. Schiff, Pankaj Patel,

Hepatology · 2021 · 335 citations · 28 references

DOIFull text

Open access

Abstract

Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).

References

28

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

David C. Goff, Donald M. Lloyd‐Jones, Glen C. Bennett et al. · Journal of the American College of Cardiology · 2013 · 4.9K citations · Full text

Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆

Christi A Matteoni, Zobair M. Younossi, T GRAMLICH et al. · Gastroenterology · 1999 · 3.4K citations

, , +12

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.2K citations · Full text

Nonalcoholic Fatty Liver Disease

Giulio Marchesini, Mara Brizi, Giampaolo Bianchi et al. · Diabetes · 2001 · 2.6K citations · Full text

Association of nonalcoholic fatty liver disease with insulin resistance

Giulio Marchesini, Mara Brizi, Antonio Maria Morselli‐Labate et al. · The American Journal of Medicine · 1999 · 1.6K citations

, , +12